A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients with the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome (ROCKIT-1 ROCK Inhibitor in Tauopathies-1)
Please go to ClinicalTrials.gov for more information.